SPONSOR
D3 Bio (Wuxi) Co., Ltd
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 1, Phase 2
D3 Bio (Wuxi) Co., Ltd is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including KRAS P.G12D, KRAS P.G12C, HER-2 Positive Advanced Solid Tumors.
The trial portfolio spans Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — D3 Bio (Wuxi) Co., Ltd
How many clinical trials has D3 Bio (Wuxi) Co., Ltd sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by D3 Bio (Wuxi) Co., Ltd, of which 3 are actively recruiting participants. These trials cover conditions including KRAS P.G12D, KRAS P.G12C, HER-2 Positive Advanced Solid Tumors. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does D3 Bio (Wuxi) Co., Ltd research focus on?
D3 Bio (Wuxi) Co., Ltd clinical trials span KRAS P.G12D, KRAS P.G12C, HER-2 Positive Advanced Solid Tumors. The research pipeline includes Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a D3 Bio (Wuxi) Co., Ltd clinical trial?
To participate in a D3 Bio (Wuxi) Co., Ltd trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all D3 Bio (Wuxi) Co., Ltd trials with current recruitment status updated daily.
Clinical Trials by D3 Bio (Wuxi) Co., Ltd
NCT07456046 Phase 1
Recruiting
A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.
KRAS P.G12D
NCT05410145 Phase 1, Phase 2
Recruiting
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
KRAS P.G12C
NCT05957536 Phase 1
Recruiting
A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors
HER-2 Positive Advanced Solid Tumors
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology